These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18373166)

  • 1. Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.
    Fujino Y; Sakai T; Kuroda Y
    J Gastroenterol; 2008; 43(3):233-8. PubMed ID: 18373166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy.
    Bahra M; Pratschke J; Klein F; Neuhaus P; Boas-Knoop S; Puhl G; Denecke T; Pullankavumkal JR; Sinn M; Riess H; Pelzer U
    Pancreas; 2015 Aug; 44(6):930-6. PubMed ID: 25931260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
    Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
    Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case.
    Matsuda T; Taniguchi F; Minato H; Nomura H; Tsuda T; Aikawa I
    Surg Today; 2006; 36(8):754-7. PubMed ID: 16865525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study.
    Skau Rasmussen L; Vittrup B; Ladekarl M; Pfeiffer P; Karen Yilmaz M; Østergaard Poulsen L; Østerlind K; Palnæs Hansen C; Bau Mortensen M; Viborg Mortensen F; Sall M; Detlefsen S; Bøgsted M; Wilki Fristrup C
    Acta Oncol; 2019 Jun; 58(6):864-871. PubMed ID: 30905248
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
    Fujino Y; Ueda T; Kamigaki T; Takase S; Ajiki T; Kamoda Y; Matsumoto I; Yasuda T; Kuroda Y
    Pancreas; 2007 Apr; 34(3):335-9. PubMed ID: 17414056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
    Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Kobayashi S; Ueno M; Morimoto M; Shiozawa M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S116-S121. PubMed ID: 33380664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma.
    Mattiucci GC; Ippolito E; D'Agostino GR; Alfieri S; Antinori A; Crucitti A; Balducci M; Deodato F; Luzi S; Macchia G; Smaniotto D; Morganti AG; Valentini V
    Ann Surg Oncol; 2013 Feb; 20(2):423-9. PubMed ID: 23208130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and prognostic factors of unresectable pancreatic cancer.
    Park JK; Yoon YB; Kim YT; Ryu JK; Yoon WJ; Lee SH
    J Clin Gastroenterol; 2008 Jan; 42(1):86-91. PubMed ID: 18097296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer.
    Nakamura M; Kayashima T; Fujiwara K; Nagayoshi Y; Kono H; Ohtsuka T; Takahata S; Mizumoto K; Tanaka M
    Hepatogastroenterology; 2013; 60(122):354-7. PubMed ID: 23574657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
    Shimoda M; Kubota K; Shimizu T; Katoh M
    Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices.
    Koeppler H; Duru M; Grundheber M; Heymanns J; Jacobs G; Pandorf A; Rendenbach B; Schimke J; Weide R
    J Support Oncol; 2004; 2(2):159-63. PubMed ID: 15328818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
    Lakatos G; Balázs A; Kui B; Gódi S; Szücs Á; Szentesi A; Szentkereszty Z; Szmola R; Kelemen D; Papp R; Vincze Á; Czimmer J; Pár G; Bajor J; Szabó I; Izbéki F; Halász A; Leindler L; Farkas G; Takács T; Czakó L; Szepes Z; Hegyi P; Kahán Z
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):219-25. PubMed ID: 27308654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.